Oncolytic virus-based immunotherapies for hepatocellular carcinoma
- Document Type
- Publications · Review Article
- Registered DB
- SCIEScopus
- Journal Ranking
- JCR Q2Scopus Q2
- Journal
- MEDIATORS OF INFLAMMATION2017 · 2017
- Citation
- Web of Science 40Scopus 44
- FWCI (Scopus)
- 0.42
- JCR IF
- JCR 2016 3.232
- ISSN
- 0962-9351
Authors
- Yoo, So YoungFirst authorCorresponding authorBIO-IT Foundry Technology Institute, Pusan National University, Busan, South Korea
- Badrinath, NarayanasamyBIO-IT Foundry Technology Institute, Pusan National University, Busan, South Korea
- Woo, Hyung-youngDepartment of Internal Medicine, College of Medicine, Pusan National University, Medical Research Institute, Yangsan, South Korea
- Heo, JeongDepartment of Internal Medicine, College of Medicine, Pusan National University, Medical Research Institute, Yangsan, South Korea
Abstract
Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.
Identifiers
- Scopus EID
- 2-s2.0-85018993312
- WoS UID
- 000399497700001



Login
Back to Publication list